Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Plast Reconstr Surg Glob Open ; 11(6): e5064, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37325370

ABSTRACT

With high success rates of autologous breast reconstruction, the focus has shifted from flap survival to improved patient outcomes. Historically, a criticism of autologous breast reconstruction has been the length of hospital stay. Our institution has progressively shortened the length of stay after deep inferior epigastric artery perforator (DIEP) flap reconstruction and began discharging select patients on postoperative day 1 (POD1). The purpose of this study was to document our experience with POD1 discharges and to identify preoperative and intraoperative factors that may identify patients as candidates for earlier discharge. Methods: An institutional review board-approved, retrospective chart review of patients undergoing DIEP flap breast reconstruction from January 2019 to March 2022 at Atrium Health was completed, consisting of 510 patients and 846 DIEP flaps. Patient demographics, medical history, operative course, and postoperative complications were collected. Results: Twenty-three patients totaling 33 DIEP flaps were discharged on POD1. The POD1 group and the group of all other patients (POD2+) had no difference in age, ASA score, or comorbidities. BMI was significantly lower in the POD1 group (P = 0.039). Overall operative time was significantly lower in the POD1 group, and this remained true when differentiating into unilateral operations (P = 0.023) and bilateral operations (P = 0.01). No major complications occurred in those discharged on POD1. Conclusions: POD1 discharge after DIEP flap breast reconstruction is safe for select patients. Lower BMI and shorter operative times may be predictive in identifying patients as candidates for earlier discharge.

2.
Int J Mol Sci ; 22(11)2021 May 25.
Article in English | MEDLINE | ID: mdl-34070369

ABSTRACT

Folate receptor beta (FRß) is a folate binding receptor expressed on myeloid lineage hematopoietic cells. FRß is commonly expressed at high levels on malignant blasts in patients with acute myeloid leukemia (AML), as well as on M2 polarized tumor-associated macrophages (TAMs) in the tumor microenvironment of many solid tumors. Therefore, FRß is a potential target for both direct and indirect cancer therapy. We demonstrate that FRß is expressed in both AML cell lines and patient-derived AML samples and that a high-affinity monoclonal antibody against FRß (m909) has the ability to cause dose- and expression-dependent ADCC against these cells in vitro. Importantly, we find that administration of m909 has a significant impact on tumor growth in a humanized mouse model of AML. Surprisingly, m909 functions in vivo with and without the infusion of human NK cells as mediators of ADCC, suggesting potential involvement of mouse macrophages as effector cells. We also found that TAMs from primary ovarian ascites samples expressed appreciable levels of FRß and that m909 has the ability to cause ADCC in these samples. These results indicate that the targeting of FRß using m909 has the potential to limit the outgrowth of AML in vitro and in vivo. Additionally, m909 causes cytotoxicity to TAMs in the tumor microenvironment of ovarian cancer warranting further investigation of m909 and its derivatives as therapeutic agents in patients with FRß-expressing cancers.


Subject(s)
Antineoplastic Agents, Immunological/pharmacology , Folate Receptor 2 , Immunotherapy , Leukemia, Myeloid, Acute , Neoplasm Proteins , Ovarian Neoplasms , Animals , CHO Cells , Cricetulus , Female , Folate Receptor 2/antagonists & inhibitors , Folate Receptor 2/immunology , HL-60 Cells , Humans , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/pathology , Leukemia, Myeloid, Acute/therapy , Mice , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/immunology , Ovarian Neoplasms/immunology , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , THP-1 Cells , Xenograft Model Antitumor Assays
3.
J Reconstr Microsurg ; 33(1): 8-18, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27595188

ABSTRACT

Background The purpose of this study was to evaluate the use of a biosynthetic mesh onlay on reducing postoperative abdominal bulge following deep inferior epigastric perforator (DIEP) flap breast reconstruction. Methods All patients undergoing DIEP reconstructions from January, 2010 to January, 2014 at a tertiary center were reviewed. Patients were divided into two groups for comparison based on whether a biosynthetic mesh onlay (Phasix [monofilament poly-4-hydroxybutyrate], Bard Inc., Warwick, RI) was used for reinforcement of the anterior rectus fascia. Rates of postoperative abdominal bulge were compared between the groups utilizing standard statistical methods. Results During the study period, 319 patients underwent 553 DIEP reconstructions, 160 (50.2%) used mesh and 159 (49.8%) did not (nonmesh). The mean follow-up was 16.4 ± 11.1 months. There was no difference in age (49 ± 9.3 years), current tobacco use, diabetes, or mean body mass index (BMI, 29.4 ± 4.4) between the mesh and nonmesh groups (p > 0.05); however, there was a higher proportion of obese patients (BMI > 30) in the mesh group (45.0 vs. 33.3%; p = 0.03). Abdominal bulge rate following DIEP with mesh was lower than the nonmesh group (0 vs. 5.0%; p = 0.004). In the entire sample, 234 (73.4%) underwent bilateral DIEP and 85 (26.6%) underwent unilateral DIEP. In unilateral DIEP patients, the bulge rate was similar between the mesh and nonmesh groups (0 vs. 4.4%; p > 0.05); however, in bilateral DIEP patients, the bulge rate was lower in the mesh group compared with a nonmesh group (0 vs. 5.5%; p = 0.008). Conclusion Reinforcement of the anterior rectus with an onlay monofilament poly-4-hydroxybutyrate biosynthetic mesh may reduce the risk of postoperative bulge rate in patients undergoing DIEP reconstruction.


Subject(s)
Hydroxybutyrates/pharmacology , Mammaplasty/methods , Perforator Flap/blood supply , Postoperative Complications/surgery , Rectus Abdominis/blood supply , Surgical Mesh , Epigastric Arteries , Female , Follow-Up Studies , Humans , Mammaplasty/adverse effects , Middle Aged , Postoperative Complications/physiopathology , Postoperative Complications/prevention & control , Rectus Abdominis/physiopathology , Rectus Abdominis/transplantation , Retrospective Studies , Transplantation, Autologous , Treatment Outcome
4.
Environ Pollut ; 150(3): 355-62, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17442469

ABSTRACT

Soybean [Glycine max (L.) Merr.] cultivars Essex and Forrest that exhibit differences in ozone (O(3)) sensitivity were used in greenhouse experiments to investigate the role of leaf extracellular antioxidants in O(3) injury responses. Charcoal-filtered air and elevated O(3) conditions were used to assess genetic, leaf age, and O(3) effects. In both cultivars, the extracellular ascorbate pool consisted of 80-98% dehydroascorbic acid, the oxidized form of ascorbic acid (AA) that is not an antioxidant. For all combinations of genotype and O(3) treatments, extracellular AA levels were low (1-30nmolg(-1) FW) and represented 3-30% of the total antioxidant capacity. Total extracellular antioxidant capacity was twofold greater in Essex compared with Forrest, consistent with greater O(3) tolerance of Essex. The results suggest that extracellular antioxidant metabolites in addition to ascorbate contribute to detoxification of O(3) in soybean leaves and possibly affect plant sensitivity to O(3) injury.


Subject(s)
Agriculture , Air Pollutants/toxicity , Glycine max/metabolism , Ozone/toxicity , Plant Leaves/metabolism , Antioxidants/analysis , Ascorbic Acid/analysis , Dehydroascorbic Acid/analysis , Ecology , Photosynthesis , Plant Leaves/chemistry , Species Specificity , Vitamins/analysis
5.
J Am Med Inform Assoc ; 10(6): 555-62, 2003.
Article in English | MEDLINE | ID: mdl-12925542

ABSTRACT

OBJECTIVE: To determine whether sales of electrolyte products contain a signal of outbreaks of respiratory and diarrheal disease in children and, if so, how much earlier a signal relative to hospital diagnoses. DESIGN: Retrospective analysis was conducted of sales of electrolyte products and hospital diagnoses for six urban regions in three states for the period 1998 through 2001. MEASUREMENTS: Presence of signal was ascertained by measuring correlation between electrolyte sales and hospital diagnoses and the temporal relationship that maximized correlation. Earliness was the difference between the date that the exponentially weighted moving average (EWMA) method first detected an outbreak from sales and the date it first detected the outbreak from diagnoses. The coefficient of determination (r2) measured how much variance in earliness resulted from differences in sales' and diagnoses' signal strengths. RESULTS: The correlation between electrolyte sales and hospital diagnoses was 0.90 (95% CI, 0.87-0.93) at a time offset of 1.7 weeks (95% CI, 0.50-2.9), meaning that sales preceded diagnoses by 1.7 weeks. EWMA with a nine-sigma threshold detected the 18 outbreaks on average 2.4 weeks (95% CI, 0.1-4.8 weeks) earlier from sales than from diagnoses. Twelve outbreaks were first detected from sales, four were first detected from diagnoses, and two were detected simultaneously. Only 26% of variance in earliness was explained by the relative strength of the sales and diagnoses signals (r2 = 0.26). CONCLUSION: Sales of electrolyte products contain a signal of outbreaks of respiratory and diarrheal diseases in children and usually are an earlier signal than hospital diagnoses.


Subject(s)
Commerce/statistics & numerical data , Diarrhea/epidemiology , Disease Outbreaks , Fluid Therapy/statistics & numerical data , Population Surveillance/methods , Respiratory Tract Diseases/epidemiology , Algorithms , Child , Diarrhea/diagnosis , Electrolytes/therapeutic use , Humans , International Classification of Diseases , Linear Models , Respiratory Tract Diseases/diagnosis , Retrospective Studies , Sensitivity and Specificity , United States/epidemiology , Urban Health
6.
J Am Med Inform Assoc ; 10(5): 409-18, 2003.
Article in English | MEDLINE | ID: mdl-12807802

ABSTRACT

The National Retail Data Monitor receives data daily from 10,000 stores, including pharmacies, that sell health care products. These stores belong to national chains that process sales data centrally and utilize Universal Product Codes and scanners to collect sales information at the cash register. The high degree of retail sales data automation enables the monitor to collect information from thousands of store locations in near to real time for use in public health surveillance. The monitor provides user interfaces that display summary sales data on timelines and maps. Algorithms monitor the data automatically on a daily basis to detect unusual patterns of sales. The project provides the resulting data and analyses, free of charge, to health departments nationwide. Future plans include continued enrollment and support of health departments, developing methods to make the service financially self-supporting, and further refinement of the data collection system to reduce the time latency of data receipt and analysis.


Subject(s)
Commerce/statistics & numerical data , Databases, Factual , Disease Outbreaks , Electronic Data Processing , Nonprescription Drugs , Population Surveillance/methods , Algorithms , Computer Security , Delivery of Health Care , Disease Outbreaks/statistics & numerical data , Humans , Nonprescription Drugs/economics , United States , User-Computer Interface
SELECTION OF CITATIONS
SEARCH DETAIL
...